OptimizeRx(OPRX) - 2025 Q1 - Quarterly Report

Commission File Number: 001-38543 OptimizeRx Corporation Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 o Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ (Exact name of registrant as specified in its charter) (State or other jurisdictio ...